Condition: Rabies Post-exposure Prophylaxis · Sponsor: Synermore Biologics (Suzhou) Co., Ltd.
This observational study is an open-label, prospective, multi-center design. The goal is to evaluate the long-term clinical survival outcomes at 3 months and 1 year in individuals under 18 years of age with WHO Category III rabies exposure who have received real-world Post-Exposure Prophylaxis (PEP) with Zamerovimab and Mazorelvimab Injection / other passive immunization products combined with the rabies vaccine. Participants will: (1) Have their clinical protection outcomes (rabies-free survival status) registered and evaluated on Day 90 and Day 365. (2) Have the option to provide a blood sample on Day 7 for Rabies Virus Neutralizing Antibody (RVNA) testing. (3) Have all adverse events (within 42 days) and all serious adverse events (within 126 days) after PEP administration collected and recorded.
This description comes directly from the study's public registry record.
Xiangjun Li · +86 0512-8765807 · xjli@synermore.cn
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Shenzhen second people's hospital | Shenzhen, Guangdong, China | Recruiting |
| The University of Hong Kong - Shenzhen Hospital | Shenzhen, Guangdong, China | Recruiting |
| Hunan Provincial People's Hospital | Changsha, Hunan, China | Recruiting |
| Affiliated Nanhua Hospital, University of South China | Hengyang, Hunan, China | Recruiting |
| Jiangxi Provincial Chest Hospital | Nanchang, Jiangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07327307